1. The Joint United Nations Programme on HIV/AIDS (UNAIDS)/World Health Organization (WHO). Epidemiological fact sheet: HIV statistics, globally and by WHO region, 2023. UNAIDS/WHO; 2023.
7. Branson BM. State of the art for diagnosis of HIV infection. Clin Infect Dis 2007;45 Suppl 4:S221-S225.
9. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011;365:493-505.
10. Moyer VA; U.S. Preventive Services Task Force. Screening for HIV: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2013;159:51-60.
11. Tsoi BW, Fine SM, McGowan JP, et al. HIV testing. Johns Hopkins University; 2022.
12. Branson BM. HIV diagnostics: current recommendations and opportunities for improvement. Infect Dis Clin North Am 2019;33:611-628.
13. Delaney KP, Hanson DL, Masciotra S, Ethridge SF, Wesolowski L, Owen SM. Time until emergence of HIV test reactivity following infection with hiv-1: implications for interpreting test results and retesting after exposure. Clin Infect Dis 2017;64:53-59.
14. Fiebig EW, Wright DJ, Rawal BD, et al. Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection. AIDS 2003;17:1871-1879.
16. Bäcker U, Gathof A, Howe J, et al. A new second-generation anti-HIV-1 enzyme immunoassay using recombinant envelope and core proteins. AIDS 1988;2:477-480.
17. Yeom JS, Lee JB, Ryu SH, et al. Evaluation of a new third-generation ELISA for the detection of HIV infection. Ann Clin Lab Sci 2006;36:73-78.
18. Branson BM, Owen SM, Wesolowski LG, et al. Laboratory testing for the diagnosis of HIV infection: updated recommendations. Centers for Disease Control and Prevention. Updated June 27, 2014. Accessed November 9, 2023.
https://stacks.cdc.gov/view/cdc/23447
22. Miller M, Cevigney R, Ayyash M, Shaman M, Kole M. False-positive human immunodeficiency virus screening results in pregnancy during the coronavirus disease 2019 (COVID-19) pandemic. Obstet Gynecol 2023;142:381-383.
24. Lee DA, Eby WC, Molinaro GA. HIV false positivity after hepatitis B vaccination. Lancet 1992;339:1060.
25. Hsia J. False-positive ELISA for human immunodeficiency virus after influenza vaccination. J Infect Dis 1993;167:989-990.
27. Gray ER, Bain R, Varsaneux O, Peeling RW, Stevens MM, McKendry RA. p24 revisited: a landscape review of antigen detection for early HIV diagnosis. AIDS 2018;32:2089-2102.
28. Opollo V, Nyakeriga E, Kingwara L, et al. Evaluation of the performance of OraQuick rapid HIV-1/2 test among decedents in Kisumu, Kenya. J Acquir Immune Defic Syndr 2022;89:282-287.
29. Yoo SJ, Sohn YH, Choi SE, Oh HB. [Meta-analysis for the pooled sensitivity and specificity of anti-human immunodeficiency virus Ab rapid tests]. Korean J Lab Med 2009;29:345-352. Korean.
30. Peters PJ, Westheimer E, Cohen S, et al. Screening yield of HIV antigen/antibody combination and pooled HIV RNA testing for acute HIV infection in a high-prevalence population. JAMA 2016;315:682-690.
32. Dorri Y. Immunoblotting of antigens: whole, strip, and newline nitrocellulose membrane immunoblotting using the chemiluminescence technique. Methods Mol Biol 2015;1314:79-94.
34. Centers for Disease Control and Prevention (CDC). Detection of acute HIV infection in two evaluations of a new HIV diagnostic testing algorithm: United States, 2011-2013. MMWR Morb Mortal Wkly Rep 2013;62:489-94.
35. Patel P, Mackellar D, Simmons P, et al. Detecting acute human immunodeficiency virus infection using 3 different screening immunoassays and nucleic acid amplification testing for human immunodeficiency virus RNA, 2006-2008. Arch Intern Med 2010;170:66-74.
36. Masciotra S, McDougal JS, Feldman J, Sprinkle P, Wesolowski L, Owen SM. Evaluation of an alternative HIV diagnostic algorithm using specimens from seroconversion panels and persons with established HIV infections. J Clin Virol 2011;52 Suppl 1:S17-S22.
37. De Cock KM, Porter A, Kouadio J, et al. Cross-reactivity on western blots in HIV-1 and HIV-2 infections. AIDS 1991;5:859-863.
40. Loussert-Ajaka I, Ly TD, Chaix ML, et al. HIV-1/HIV-2 seronegativity in HIV-1 subtype O infected patients. Lancet 1994;343:1393-1394.
41. World Health Organization. Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach. Accessed December 30, 2023.
https://www.ncbi.nlm.nih.gov/books/NBK572729/
42. US Preventive Services Task Force, Owens DK, Davidson KW, et al. Preexposure prophylaxis for the prevention of HIV infection: US Preventive Services Task Force recommendation statement. JAMA 2019;321:2203-2213.
43. Clinical and Laboratory Standards Institute (CLSI). Criteria for laboratory testing and diagnosis of human immunodeficiency virus infection. Approved guideline CLSI document M53. CLSI; 2023.
44. Conrad S, Gant Kanegusuku A, Conklin SE. Taking a step back from testing: preanalytical considerations in molecular infectious disease diagnostics. Clin Biochem 2023;115:22-32.
47. O’Brien SF, Yi QL, Fan W, Scalia V, Kleinman SH, Vamvakas EC. Current incidence and estimated residual risk of transfusion-transmitted infections in donations made to Canadian Blood Services. Transfusion 2007;47:316-325.
49. Kang JW, Shin S, Seo DH, et al. Estimation of the residual risk of transfusion-transmissible infectious agents in Korea. Korean J Blood Transfus 2019;30:156-162.
50. Hanna GJ, D’Aquila RT. Clinical use of genotypic and phenotypic drug resistance testing to monitor antiretroviral chemotherapy. Clin Infect Dis 2001;32:774-782.
51. HHS Panel on Antiretroviral Guidelines for Adults and Adolescents—A Working Group of the Office of AIDS Research Advisory Council (OARAC). Guidelines for the use of antiretroviral agents in adults and adolescents with HIVS Accessed December 30, 2023.
https://www.ncbi.nlm.nih.gov/books/NBK586306/